Effects of Azimilide Dihydrochloride on Circus Movement Atrial Flutter in the Canine Sterile Pericarditis Model

Restivo, Mark; Hegazy, M.; Caref, Edward B.; Avitable, Matthew; Assadi, Mahshid A.; El-Hamami, Moustafa; Yin, Hong; Piracha, Muhammad Usman; Brooks, Robert R.; El‐Sherif, Nabil

doi:10.1111/j.1540-8167.1996.tb00569.x

Cited by 25 publications

(24 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AF could be reinduced in these dogs but not after a cumulative dose of 10 mgkg. Azimilide increased the cycle length of the last reentry circuit before termination and acted preferentially to increase atrial ERP in the zone of slow conduction (46).…”

Section: Atrial Arrhythmiasmentioning

confidence: 96%

Pharmacology of Azimilide Dihydrochloride (NE‐10064), A Class III Antiarrhythmic Agent

Salata

Brooks

1997

Cardiovascular Drug Reviews

Self Cite

View full text Add to dashboard Cite

Section: Atrial Arrhythmiasmentioning

confidence: 96%

Pharmacology of Azimilide Dihydrochloride (NE‐10064), A Class III Antiarrhythmic Agent

Salata

Brooks

1997

Cardiovascular Drug Reviews

Self Cite

View full text Add to dashboard Cite

“…In open-chest, anesthetized dogs without MI, the combination of 10 mg/kg intravenous azimilide and strong left stellate ganglionic stimulation resulted in VT [107]. Transient premature ventricular contractions and torsade de pointes have also been reported in dogs treated with azimilide [104,108]. In a rabbit model of proarrhythmia, azimilide had a lower probability of causing life-threatening arrhythmias than did other class III agents (e.g., sotalol, dofetilide) administered at pharmacologically equivalent doses [112].…”

Section: Adamsonmentioning

confidence: 92%

“…In one model of sudden cardiac death in postinfarction dogs in which exercise and ischemia were combined, intravenous azimilide, 10 mg/kg, protected only 1 of 10 dogs from ventricular fibrillation [107]. But in another model of sudden cardiac death (a thrombus-induced, secondary-site, ischemic event within 1 week of a primary myocardial infarction [MI]), intravenous azimilide, 10 mg/kg, protected 8 of 12 dogs from sudden death [108].…”

Section: Adamsonmentioning

confidence: 99%

Pharmacological Treatment of Atrial Fibrillation: Mechanisms of Action and Efficacy of Class III Drugs

Lombardi¹,

Terranova

2006

CMC

View full text Add to dashboard Cite

Atrial fibrillation represents a major clinical, social and economical matter, and its importance is expected to increase even more in the near future. The progressive ageing of population is associated with an inevitable rising in incidence and prevalence of this rhythm disorder, which limits functional capability, favours occurrence of cerebrovascular events and increases people's request for emergency room visits and hospital recovery. In spite of the increasing successes of the interventional non-pharmacological therapies, drug treatment of patients with atrial fibrillation in relation to conversion to sinus rhythm and prevention of recurrences, maintains a critical role. Several antiarrhythmic drugs are nowadays available, but their efficacy is limited by the high rate of arrhythmias recurrences and by side effects during acute and chronic treatment. Drugs interfering with potassium channels (Class III drugs) have been proposed and used in patients with atrial fibrillation. Aim of this review is to discuss the most recent data on the efficacy and feasibility of class III drugs in atrial fibrillation. Experimental and clinical data on dronedarone, ibutilide, dofetilide, azimilide, ersentilide and ambasilide will be hereby discussed.

show abstract

“…It differs structurally from the methane-sulfonamide-substituted agents, such as sotalol, dofetilide, or ibutilide. Although it is not a benzofuran derivative, in many respects, azimilide resembles amiodarone, which also maintains a class III effect at high stimulation frequencies (71)(72)(73)(74)(75)(76)(77). The terminal half-life of azimilide is 4 to 5 days, it can be administered once daily, and it is eliminated by hepatic metabolism (75).…”

Section: Antiarrhythmic Drugs Under Developmentmentioning

confidence: 99%

Atrial Fibrillation: Epidemiologic Considerations and Rationale for Conversion and Maintenance of Sinus Rhythm

Singh

2003

J Cardiovasc Pharmacol Ther

View full text Add to dashboard Cite

Atrial fibrillation is now the most common cardiac arrhythmia for which a patient is hospitalized. Clinically, it presents in a form that is paroxysmal, persistent, or permanent and may be symptomatic or asymptomatic, occurring in the setting of either no cardiac disease ("lone atrial fibrillation") or, most often, in association with an underlying disease. Atrial fibrillation is associated with a 2-fold increase in mortality and, in the United States alone, causes over 75,000 cases of stroke per year. The annual prevalence of stroke is 5% to 7%, but the use of adequate anticoagulation can reduce this to less than 1%. Atrial fibrillation is a disorder of the elderly, with almost equal prevalence in men and women. In the United States, 80% of atrial fibrillation occurs in patients over the age of 65 years, and its prevalence tracks that of heart failure, which may be the cause, as well as the result, of the arrhythmia. Both conditions are increasing in epidemic proportions in the aging population. The most common causes of atrial fibrillation are hypertensive heart disease, coronary artery disease, and heart failure with a miscellany of lesser conditions, with about 10% lacking structural heart disease. Unlike other supraventricular arrhythmias, cure by the use of catheter ablation and surgical techniques has not been a reality except in a relatively small number of cases. However, restoration and maintenance of sinus rhythm remain the initial goal of therapy for most patients. Pharmacologic approaches remain the mainstay of therapy for rate control and anticoagulation as well as for maintenance of sinus rhythm following pharmacological or electrical conversion. The changing epidemiology of atrial fibrillation is highlighted, with the focus on its conversion by the use of newer and novel antifibrillatory agents relative to the mechanisms of the arrhythmia, to restore the stability of sinus rhythm.

show abstract

Effects of Azimilide Dihydrochloride on Circus Movement Atrial Flutter in the Canine Sterile Pericarditis Model

Cited by 25 publications

References 33 publications

Pharmacology of Azimilide Dihydrochloride (NE‐10064), A Class III Antiarrhythmic Agent

Pharmacology of Azimilide Dihydrochloride (NE‐10064), A Class III Antiarrhythmic Agent

Pharmacological Treatment of Atrial Fibrillation: Mechanisms of Action and Efficacy of Class III Drugs

Atrial Fibrillation: Epidemiologic Considerations and Rationale for Conversion and Maintenance of Sinus Rhythm

Contact Info

Product

Resources

About